Table 4 Stratified analyses for associations between blood sodium levels and VTE outcome
| Â | Sodium (mEq/L) | ||
|---|---|---|---|
|  | < 135 | 135–145 | > 145 |
|  | (n = 87,476) | (n = 1,010,167) | (n = 11,061) |
Thromboembolism | 1.43 (1.36–1.52) | Reference | 1.57 (1.38–1.78) |
Age | |||
  < 50 (n = 337,832) | 1.68 (1.45–1.94) | Reference | 1.65 (1.14–2.38) |
 50–64 (n = 360,216) | 1.65 (1.49–1.83) | Reference | 1.42 (1.11–1.82) |
 65–79 (n = 302,870) | 1.28 (1.17–1.41) | Reference | 1.67 (1.37–2.03) |
  ≥ 80 (n = 107,786) | 1.17 (1.02–1.33) | Reference | 1.40 (1.06–1.83) |
Sex | |||
 Male (n = 484,893) | 1.37 (1.27–1.48) | Reference | 1.54 (1.29–1.84) |
 Female (n = 623,811) | 1.48 (1.36–1.60) | Reference | 1.57 (1.31–1.88) |
Surgical specialty | |||
 Non-orthopedic (n = 1,013,787) | 1.47 (1.39–1.56) | Reference | 1.62 (1.43–1.85) |
 Orthopedic (n = 94,917) | 1.10 (0.89–1.37) | Reference | 0.71 (0.34–1.51) |
Steroid use for chronic condition | |||
 No (n = 1,070,536) | 1.45 (1.37–1.54) | Reference | 1.66 (1.46–1.89) |
 Yes (n = 38,168) | 1.26 (1.06–1.51) | Reference | 0.86 (0.53–1.39) |
BMI | |||
  < 18.5 (n = 24,770) | 1.28 (1.00–1.63) | Reference | 1.68 (0.92–3.07) |
 18.5–24.9 (n = 279,799) | 1.51 (1.36–1.66) | Reference | 1.52 (1.19–1.95) |
 25.0–29.9 (n = 328,295) | 1.44 (1.30–1.60) | Reference | 1.50 (1.17–1.93) |
 30.0–34.9 (n = 238,890) | 1.30 (1.15–1.48) | Reference | 1.45 (1.12–1.89) |
  ≥ 35.0 (n = 236,950) | 1.52 (1.32–1.74) | Reference | 1.82 (1.39–2.38) |
Presence of active cancera | |||
 No (n = 1,068,670) | 1.42 (1.34–1.51) | Reference | 1.53 (1.34–1.74) |
 Yes (n = 40,034) | 1.25 (1.04–1.49) | Reference | 1.55 (1.29–1.85) |
Chemotherapy for malignancy ≤30 days pre-surgery | |||
 No (n = 1,091,517) | 1.42 (1.34–1.51) | Reference | 1.57 (1.38–1.78) |
 Yes (n = 17,187) | 1.67 (1.29–2.16) | Reference | 1.57 (0.79–3.13) |